The outcomes affirm conclusions drawn by Bagli et al. [one], who done a review that incorporated 10 patients diagnosed with CRAO who received HBOT. Together with getting twenty classes of HBOT, oral acetazolamide and topical beta-blockers were administered into the patients in the earliest possible